These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34192388)

  • 1. SCR7, an inhibitor of NHEJ can sensitize tumor cells to ionization radiation.
    Gopalakrishnan V; Sharma S; Ray U; Manjunath M; Lakshmanan D; Vartak SV; Gopinatha VK; Srivastava M; Kempegowda M; Choudhary B; Raghavan SC
    Mol Carcinog; 2021 Sep; 60(9):627-643. PubMed ID: 34192388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner.
    Vartak SV; Swarup HA; Gopalakrishnan V; Gopinatha VK; Ropars V; Nambiar M; John F; Kothanahally SKS; Kumari R; Kumari N; Ray U; Radha G; Dinesh D; Pandey M; Ananda H; Karki SS; Srivastava M; Charbonnier JB; Choudhary B; Mantelingu K; Raghavan SC
    FEBS J; 2018 Nov; 285(21):3959-3976. PubMed ID: 30230716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics.
    Ray U; Raul SK; Gopinatha VK; Ghosh D; Rangappa KS; Mantelingu K; Raghavan SC
    Mol Carcinog; 2020 Jun; 59(6):618-628. PubMed ID: 32189406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end-joining.
    Manjunath M; Choudhary B; Raghavan SC
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1341. PubMed ID: 33496064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
    Greco GE; Matsumoto Y; Brooks RC; Lu Z; Lieber MR; Tomkinson AE
    DNA Repair (Amst); 2016 Jul; 43():18-23. PubMed ID: 27235626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression.
    Srivastava M; Nambiar M; Sharma S; Karki SS; Goldsmith G; Hegde M; Kumar S; Pandey M; Singh RK; Ray P; Natarajan R; Kelkar M; De A; Choudhary B; Raghavan SC
    Cell; 2012 Dec; 151(7):1474-87. PubMed ID: 23260137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
    Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
    Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pluronic copolymer encapsulated SCR7 as a potential anticancer agent.
    John F; George J; Srivastava M; Hassan PA; Aswal VK; Karki SS; Raghavan SC
    Faraday Discuss; 2015; 177():155-61. PubMed ID: 25608025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing.
    Vartak SV; Raghavan SC
    FEBS J; 2015 Nov; 282(22):4289-94. PubMed ID: 26290158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced efficacy of pluronic copolymer micelle encapsulated SCR7 against cancer cell proliferation.
    John F; George J; Vartak SV; Srivastava M; Hassan PA; Aswal VK; Karki SS; Raghavan SC
    Macromol Biosci; 2015 Apr; 15(4):521-34. PubMed ID: 25515310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
    Soni A; Siemann M; Pantelias GE; Iliakis G
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.
    Maruyama T; Dougan SK; Truttmann MC; Bilate AM; Ingram JR; Ploegh HL
    Nat Biotechnol; 2015 May; 33(5):538-42. PubMed ID: 25798939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NHEJ inhibitor SCR7 and its different forms: Promising CRISPR tools for genome engineering.
    Ray U; Vartak SV; Raghavan SC
    Gene; 2020 Dec; 763():144997. PubMed ID: 32783992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA ligase IV and artemis act cooperatively to suppress homologous recombination in human cells: implications for DNA double-strand break repair.
    Kurosawa A; Saito S; So S; Hashimoto M; Iwabuchi K; Watabe H; Adachi N
    PLoS One; 2013; 8(8):e72253. PubMed ID: 23967291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside Analogs Radiosensitize G0 Cells by Activating DNA End Resection and Alternative End-Joining.
    Magin S; Meher PK; Iliakis G
    Radiat Res; 2021 May; 195(5):412-426. PubMed ID: 33755161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair.
    Dong J; Ren Y; Zhang T; Wang Z; Ling CC; Li GC; He F; Wang C; Wen B
    Oncol Rep; 2018 Mar; 39(3):912-920. PubMed ID: 29344644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of ligatable "clean" double-strand break ends is the rate-limiting step in the rejoining of ionizing-radiation-induced DNA breakage.
    Sasanuma H; Yamada S; Tsuda M; Takeda S
    DNA Repair (Amst); 2020 Sep; 93():102913. PubMed ID: 33087279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of mercaptopyrimidine-based small molecules as inhibitors of nonhomologous DNA end joining.
    Ray U; Gopinatha VK; Sharma S; Goyary L; Choudhary B; Mantelingu K; Rangappa KS; Raghavan SC
    FEBS J; 2023 Feb; 290(3):796-820. PubMed ID: 36048168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
    Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
    Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
    Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
    Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.